文献速递造血干细胞移植与细胞治疗

仅8名供者构建的CMV特异性T细胞「迷你」库可覆盖多数异基因HSCT受者

"Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients.
PubMed 文献 · Blood Adv · 2019-01-01

该研究报告建立了一个仅含8名CMV血清阳性供者的CMV特异性T细胞(CMVST)库,HLA型别覆盖美国多样人群。筛查29例患者中28例(96.6%)可匹配到共享≥2个HLA抗原的细胞系,10例难治性CMV感染/病患者单次输注后获3例部分缓解和7例完全缓解,累计应答率100%(95%CI 69.2-100),未见GVHD、移植物失败或细胞因子释放综合征。

要点

  • 8名供者CMVST库可为96.6%(28/29)患者匹配到共享≥2个HLA抗原的细胞系。
  • 10例难治性CMV感染/病患者单次输注后累计应答率100%(95%CI 69.2-100)。
  • 单次供者采集可制备>2000次输注所需细胞,利于跨中心推广。

核心结论

  • 仅8名精选第三方供者构建的CMVST「迷你」库可为多数异基因HSCT后患者提供匹配细胞系,并产生安全有效的抗CMV活性。

研究设计与样本

  • 研究报告了8名CMV血清阳性供者来源CMVST库的建立与使用,HLA型别代表美国多样人群。
  • 共筛查29例患者,28例(96.6%)匹配到共享≥2个HLA抗原的细胞系,共享HLA抗原中位数为4个。
  • 10例持续/难治性CMV感染或病患者接受单次CMVST输注。

主要发现

  • 10例可评估患者中,单次输注产生3例部分缓解和7例完全缓解。
  • 累计应答率为100%(95%置信区间,69.2-100)。
  • 未见移植物抗宿主病、移植物失败或细胞因子释放综合征。
  • 单次供者采集可产生足够材料制备>2000次输注的细胞。

临床怎么用

  • 对于异基因HSCT后难治性CMV感染/病,可考虑从预先建立的第三方CMVST库中匹配共享≥2个HLA抗原的细胞系进行单次输注。
  • 该策略的安全性表现为未见GVHD、移植物失败或细胞因子释放综合征。
  • 单次供者采集可制备>2000次输注,支持跨移植中心广泛使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytomegalovirus (CMV) infections remain a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), and standard antiviral therapies are associated with significant side effects and development of drug-resistant mutants. Adoptively transferred donor-derived CMV-specific T cells (CMVSTs) can provide an alternative treatment modality with few side effects but are not widely available due to their patient-specific nature. Here we report the establishment and use of a bank of CMVSTs derived from just 8 CMV-seropositive donors, with HLA types representing the diverse US population, as an "off-the-shelf" therapy to treat drug-refractory infections. To date, we have screened 29 patients for study participation and identified a suitable line, with ≥2 of 8 shared HLA antigens, for 28 (96.6%) patients with a median of 4 shared HLA antigens. Of these, 10 patients with persistent/refractory CMV infections or disease were eligible for treatment; a single infusion of cells produced 3 partial responses and 7 complete responses, for a cumulative response rate of 100% (95% confidence interval, 69.2-100) with no graft-versus-host disease, graft failure, or cytokine release syndrome. Potential wider use of the tested CMVSTs across transplant centers is made more feasible by our ability to produce sufficient material to generate cells for >2000 infusions from a single donor collection. Our data indicate that a "mini" bank of CMVSTs prepared from just 8 well-chosen third-party donors can supply the majority of patients with an appropriately matched line that produces safe and effective anti-CMV activity post-HSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tzannou I, Watanabe A, Naik S, et al. "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Adv. 2019. PMID: 31481503. doi:10.1182/bloodadvances.2019000371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。